To recover your password please fill in your email address
Please fill in below form to create an account with us
A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) (ILLUMINATE)
See ANZCTR for full trial details >
|
Trial Summary: |
To evaluate the efficacy and tolerability of dual blockade combination durvalumab and tremelimumab with platinum-pemetrexed in patients with metastatic NSCLC (T790+ve or T790M-ve) who progressed on EGFR- Tyrosine Kinase Inhibitors. |
|
Supported By: |
AstraZeneca |
|
Eligibility: |
Adults with relapsed non-squamous NSCLC with EGFR mutation with or without T790M mutation. |
|
Registration ID: |
ACTRN12618001742268 |
|
Participation: |
Australia & Taiwan |
|
Status: |
In follow-up |
|
Activation Date: |
Q1 2019 |
|
Chairs: |
A/Prof Chee Lee (St George Hospital) |
|
Contact: |